SCHEMBL177738

SCHEMBL177738

Oc1ccc(Br)c(Cl)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30092807 1.00
Phenylboronic Acid SCHEMBL25209043 0.81 ENPP2 (0.48)
(Phenylsulfonyl)Benzene SCHEMBL10277641 0.80 POLB (0.51)
SCHEMBL29692455 0.79
SCHEMBL1889611 0.79
SCHEMBL29617570 0.75
SCHEMBL29374280 0.75
SCHEMBL1047274 0.75
SCHEMBL224868 0.75
SCHEMBL4873494 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 700 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107011280-A A kind of preparation method of the chlorobenzene of 7 bromine 6 simultaneously [D] isoxazole 无锡捷化医药科技有限公司 2017-08-04 CN claimed
US-20260109702-A1 NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF GENOSCO INC (US) 2026-04-23 US disclosed
US-20260078119-A1 DEGRADER COMPOUNDS AND USES THEREOF BRISTOL MYERS SQUIBB CO (US) 2026-03-19 US disclosed
EP-3565808-B1 COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS ARDELYX INC (US) 2026-03-04 EP disclosed
US-20260055094-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2026-02-26 US disclosed
US-20260049092-A1 ANTIBACTERIAL COMPOUNDS BLACKSMITH MEDICINES INC (US) 2026-02-19 US disclosed
EP-4688771-A1 NOVEL FAK DEGRADER COMPOUNDS AND USES THEREOF Bristol-Myers Squibb Company (US) 2026-02-11 EP disclosed
EP-4691553-A2 FXR (NR1H4) MODULATING COMPOUNDS Gilead Sciences, Inc. (US) 2026-02-11 EP disclosed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 EP disclosed
US-20260034140-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LTD (GB) 2026-02-05 US disclosed
WO-2000020389-A1 NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2000-04-13 WO disclosed
WO-2000002859-A1 N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2000-01-20 WO disclosed
US-5977105-A Compounds ASTRA PHARMAEUTICALS LTD. (GB) 1999-11-02 US disclosed
CN-1208403-A Compounds BRITISH ASTRA PHARMACEUTICALS (GB) 1999-02-17 CN disclosed
EP-0865431-A2 COMPOUNDS Astra Pharmaceuticals Limited (GB) 1998-09-23 EP disclosed
WO-1997020815-A1 COMPOUNDS ASTRA PHARMACEUTICALS LTD. (GB) 1997-06-12 WO disclosed
US-5112523-A High clearing point for liquid crystal displays CHISSO CORPORATION (JP) 1992-05-12 US disclosed
US-4874546-A LIQUID CRYSTALS CHISSO CORPORATION (JP) 1989-10-17 US disclosed
US-4287125-A Preparation of benzenoid ethers and thioethers RHONE-POULENC INDUSTRIES (FR) 1981-09-01 US disclosed
US-3965158-A Process for preparing halophenol sulfonic compounds and halophenols from halobenzene sulfonates RHONE-PROGIL (FR) 1976-06-22 US disclosed